- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Clay Alspach Explains How Changes in the FDA Will Affect Biosimilars
Clay Alspach, JD, principal, Leavitt Partners, explains how biosimilars will be affected by changes in the FDA under Scott Gottlieb's leadership.
Clay Alspach, JD, principal, Leavitt Partners, explains how biosimilars will be affected by changes in the FDA under Scott Gottlieb's leadership.
Transcript (slighly modified)
What changes in the FDA under Scott Gottlieb’s leadership do you think will have the best chance of meaningfully impacting drug prices?
It’s clear that drug pricing is a priority for President Trump, and Commissioner Gottlieb at FDA has already taken steps to prioritize generic applications. He’s also put out information on biosimilars to help educate physicians, as well as provide additional guidance for those producing them. So, I think that will be the area where they try to make the most difference.
In VERIFY, Rusfertide Spares Most Patients With PV a Phlebotomy for 32 Weeks, Improves QOL
June 3rd 2025Adding rusfertide to standard of care more than doubled the share of patients with polycythemia vera (PV) who did not meet criteria for a phlebotomy, according to data from the VERIFY trial.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Depth of Responses, PFS in Transplant-Ineligible Patients Match Overall Findings in CEPHEUS
June 2nd 2025Quadruplet therapy is now the accepted standard for patients newly diagnosed with myeloma who are ineligible for transplant; there is debate whether all newly diagnosed patients should have this regimen.
Read More
How Health Care Institutions Can Leverage Biosimilars to Generate Savings
August 17th 2022On this episode of Managed Care Cast, Ryan Haumschild, PharmD, MS, MBA, from Emory Healthcare and the Winship Cancer Institute, explains the evolution of biosimilar pharmacoeconomics and the different strategies that health care institutions can implement to reap the benefits of biosimilar savings.
Listen
Multicancer Detection Assays Remain Largely Elusive for Early-Stage Disease Detection
June 1st 2025Multicancer early detection tests are revolutionizing cancer screening by using liquid biopsies to screen for multiple cancers from a single blood sample, enhancing patient outcomes by identifying cancers earlier.
Read More
